PRESS RELEASE published on 06/20/2024 at 13:00, 2 months 29 days ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 3 months ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
BRIEF published on 06/19/2024 at 13:05, 3 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
PRESS RELEASE published on 06/19/2024 at 13:00, 3 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 3 months 1 day ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
BRIEF published on 06/18/2024 at 13:05, 3 months 1 day ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
PRESS RELEASE published on 06/18/2024 at 13:00, 3 months 1 day ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
BRIEF published on 06/14/2024 at 22:50, 3 months 5 days ago Avis de rappel d'assemblée générale annuelle et extraordinaire des actionnaires de Theralase® Actionnaires Theralase® Réunion Virtuelle AGSM Présentation Zoom
BRIEF published on 06/14/2024 at 22:50, 3 months 5 days ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase® Shareholders Theralase® Virtual Meeting AGSM Zoom Presentation
PRESS RELEASE published on 06/14/2024 at 22:45, 3 months 5 days ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders Annual General Meeting Shareholders Theralase Technologies Inc. AGSM Virtual Zoom Presentation
Published on 09/20/2024 at 02:00, 2 hours 42 minutes ago Academy of Math and Science Celebrates Hispanic Heritage Month
Published on 09/19/2024 at 23:15, 5 hours 27 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 5 hours 42 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 23:00, 5 hours 42 minutes ago Cerrado Files NI 43-101 Preliminary Economic Assessment Technical Report and Mineral Resource Estimate for The Minera Don Nicolas Mine in Santa Cruz, Argentina
Published on 09/19/2024 at 21:09, 7 hours 32 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 9 hours 58 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 10 hours 39 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 10 hours 50 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 10 hours 50 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 10 hours 57 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 10 hours 57 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 10 hours 57 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)